---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-086406"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-07-23T23:54:03+00:00"
generated_at: "2026-07-24T10:05:45.099628+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics grants stock options and FDA-contingent cash bonuses to CEO and CFO

## Summary
- CEO Robert C. Jahr granted 100,000 stock options at $1.4304/share, vesting July 21, 2027.
- CFO Lawrence A. Kenyon granted 210,078 stock options at same price and vesting schedule.
- Cash bonuses of $420,000 (Jahr) and $200,000 (Kenyon) contingent on FDA approval of ONS-5010 by July 31, 2026.
- Bonuses awarded for 2025 service contributions and BLA advancement; no 2025 annual bonuses paid.
- Options and bonuses approved by Compensation Committee on July 21, 2026.

## SEC filing metadata
- accession: 0001104659-26-086406
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-07-23T23:54:03+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926086406/0001104659-26-086406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926086406/tm2621232d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-086406
- JSON: https://secwatch.observer/filing/0001104659-26-086406.json
- Plain text: https://secwatch.observer/filing/0001104659-26-086406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.